Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial

被引：0

作者：

Jung Hyun Jo

Yong-Tae Kim

Ho Soon Choi

Ho Gak Kim

Hong Sik Lee

Young Woo Choi

Dong Uk Kim

Kwang Hyuck Lee

Eui Joo Kim

Joung-Ho Han

Seung Ok Lee

Chang-Hwan Park

Eun Kwang Choi

Jae Woo Kim

Jae Yong Cho

Woo Jin Lee

Hyungsik Roger Moon

Mi-Suk Park

Sangjae Kim

Si Young Song

机构：

[1] Yonsei University College of Medicine,Division of Gastroenterology, Department of Internal Medicine, Severance Hospital

[2] Seoul National University College of Medicine,Department of Internal Medicine and Liver Research Institute

[3] Hanyang University College of Medicine,Department of Internal Medicine

[4] Daegu Catholic University School of Medicine,Department of Internal Medicine

[5] Korea University College of Medicine,Department of Gastroenterology

[6] Konyang University College of Medicine,Department of Internal Medicine

[7] Pusan National University Hospital,Division of Gastroenterology and Hepatology, Biomedical Research Institute

[8] Sungkyunkwan University School of Medicine,Department of Medicine, Samsung Medical Center

[9] Gachon University College of Medicine,Division of Gastroenterology, Department of Internal Medicine, Gil Medical Center

[10] Chungbuk National University College of Medicine & Chungbuk National University Hospital,Department of Internal Medicine

[11] Jeonbuk National University Medical School,Department of Internal Medicine, The Research Institute for Medical Science

[12] Chonnam National University Medical School,Department of Internal Medicine

[13] Jeju National University College of Medicine,Division of Gastroenterology, Department of Internal Medicine

[14] Yonsei University Wonju College of Medicine,Department of Internal Medicine

[15] Yonsei University College of Medicine,Department of Internal Medicine, Gangnam Severance Hospital

[16] National Cancer Center,Center for Liver and Pancreatobiliary Cancer

[17] University of Southern California,Department of Economics

[18] Yonsei University,Department of Economics

[19] Yonsei University College of Medicine,Department of Radiology

[20] Severance Hospital,undefined

[21] GemVax & KAEL Co.,undefined

[22] Ltd. 58,undefined

来源：

British Journal of Cancer | 2024年 / 130卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：43 / 52

页数：9

共 30 条

[21] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Dieras, Veronique
Miles, David
Verma, Sunil
Pegram, Mark
Welslau, Manfred
Baselga, Jose
Krop, Ian E.
Blackwell, Kim
Hoersch, Silke
Xu, Jin
Green, Marjorie
Gianni, Luca
LANCET ONCOLOGY, 2017, 18 (06): : 732 - 742
[22] for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (vol 385, pg 1873, 2015)
Hillmen, P.
Robak, T.
Janssens, A.
LANCET, 2016, 387 (10026): : E24 - E24
[23] APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).
Tempero, Margaret A.
Cardin, Dana Backlund
Biankin, Andrew
Goldstein, David
Moore, Malcolm
O'Reilly, Eileen Mary
Philip, Agop Philip
Riess, Hanno
Macarulla, Teresa
Yung, Lotus
Wei, Xinyu
Lu, Brian
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[24] ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma
Neoptolemos, J.
Buechler, M.
Stocken, D. D.
Ghaneh, P.
Smith, D.
Bassi, C.
Moore, M.
Cunningham, D.
Dervenis, C.
Goldstein, D.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
[25] ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma
Neoptolemos, J.
Buechler, M.
Stocken, D. D.
Ghaneh, P.
Smith, D.
Bassi, C.
Moore, M.
Cunningham, D.
Dervenis, C.
Goldstein, D.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[26] Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE) final report of a randomised, open-label, phase 3 trial
Zhang, Xiaotian
Liang, Han
Li, Ziyu
Xue, Yingwei
Wang, Yanong
Zhou, Zhiwei
Yu, Jiren
Bu, Zhaode
Chen, Lin
Du, Yian
Wang, Xinbao
Wu, Aiwen
Li, Guoli
Su, Xiangqian
Xiao, Gang
Cui, Ming
Wu, Dan
Chen, Li
Wu, Xiaojiang
Zhou, Yanbing
Zhang, Lianhai
Dang, Chengxue
He, Yulong
Zhang, Zhongtao
Sun, Yihong
Li, Yong
Chen, Huanqiu
Bai, Yuxian
Wang, Yakun
Yu, Peiwu
Zhu, Guanbao
Suo, Jian
Jia, Baoqing
Li, Leping
Huang, Changming
Li, Fei
Ye, Yingjiang
Xu, Huimian
Wang, Xin
Yuan, Yannan
Jianyu, E.
Ying, Xiangji
Yao, Chen
Shen, Lin
Ji, Jiafu
LANCET ONCOLOGY, 2025, 26 (03): : 312 - 319
[27] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)
Dieras, V
Miles, D.
Verma, S.
LANCET ONCOLOGY, 2017, 18 (08): : E433 - E433
[28] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)
Dieras, V
Miles, D.
Verma, S.
LANCET ONCOLOGY, 2018, 19 (12): : E667 - E667
[29] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Al-Batran, Salah-Eddin
Hofheinz, Ralf D.
Pauligk, Claudia
Kopp, Hans-Georg
Haag, Georg Martin
Luley, Kim Barbara
Meiler, Johannes
Homann, Nils
Lorenzen, Sylvie
Schmalenberg, Harald
Probst, Stephan
Koenigsmann, Michael
Egger, Matthias
Prasnikar, Nicole
Caca, Karel
Trojan, Joerg
Martens, Uwe M.
Block, Andreas
Fischbach, Wolfgang
Mahlberg, Rolf
Clemens, Michael
Illerhaus, Gerald
Zirlik, Katja
Behringer, Dirk M.
Schmiegel, Wolff
Pohl, Michael
Heike, Michael
Ronellenfitsch, Ulrich
Schuler, Martin
Bechstein, Wolf O.
Koenigsrainer, Alfred
Gaiser, Timo
Schirmacher, Peter
Hozaeel, Wael
Reichart, Alexander
Goetze, Thorsten O.
Sievert, Mark
Jaeger, Elke
Moenig, Stefan
Tannapfel, Andrea
LANCET ONCOLOGY, 2016, 17 (12): : 1697 - 1708
[30] Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial (vol 22, pg 1081, 2021)
Zhang, Xiaotian
Liang, Han
Li, Ziyu
Xue, Yingwei
Wang, Yanong
Zhou, Zhiwei
Yu, Jiren
Bu, Zhaode
Chen, Lin
Du, Yian
Wang, Xinbao
Wu, Aiwen
Li, Guoli
Su, Xiangqian
Xiao, Gang
Cui, Ming
Wu, Dan
Chen, Li
Wu, Xiaojiang
Zhou, Yanbing
Zhang, Lianhai
Dang, Chengxue
He, Yulong
Zhang, Zhongtao
Sun, Yihong
Li, Yong
Chen, Huanqiu
Bai, Yuxian
Qi, Changsong
Yu, Peiwu
Zhu, Guanbao
Suo, Jian
Jia, Baoqing
Li, Leping
Huang, Changming
Li, Fei
Ye, Yingjiang
Xu, Huimian
Wang, Xin
Yuan, Yannan
Jian-Yu, E.
Ying, Xiangji
Yao, Chen
Shen, Lin
Ji, Jiafu
LANCET ONCOLOGY, 2021, 22 (08): : E347 - E347

← 1 2 3 →